youtube_live
Q3 2026 earnings • 8:00 AM today
See detailschevron_right
CMPS:NASDAQ
Compass Pathways PLC
$8.41
arrow_downward
-27.31%(-3.16) 1D
$8.79
arrow_upward
+4.52% (+0.38)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CMPS...
Open
$11.71
High
$11.76
Low
$7.54
Mkt. cap
1.16B
Avg. vol.
2.52M
Volume
0.00
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
Open
$11.71
High
$11.76
Low
$7.54
Mkt. cap
1.16B
Avg. vol.
2.52M
Volume
0.00
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
News stories
From web sources and news partners
Yahoo Finance
·
12 hours ago
CMPS, HELP Stocks On Track For Worst Day In Months On Competitive FDA Psychedelic Race Fears
The Motley Fool
·
1 day ago
1 Reason Compass Pathways Is Worth a Second Look This Month
Business Insider
·
1 week ago
After a long, strange trip, this CEO is close to taking a psilocybin pill to market
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
About Compass Pathways PLC
Analyst ratings
Based on 11 analysts giving stock ratings to CMPS in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CMPS in the last 3 months.
Highest
Current $8.41
$65.00 (+672.89%)
Average
$24.91 (+196.20%)
Lowest
$13.00 (+54.58%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Patrick Trucchio H.C. Wainwright | Buy | Maintained | $65.00 | +672.9% | 09/21/2026 |
Sumant Kulkarni Canaccord Genuity | Buy | Reiterated | $20.00 | +137.8% | 09/10/2026 |
Francois Brisebois LifeSci Capital | Buy | Reiterated | $24.00 | +185.4% | 09/09/2026 |
Benjamin Burnett Wells Fargo | Hold | Maintained | $13.00 | +54.6% | 08/31/2026 |
Paul Matteis Stifel Nicolaus | Buy | Maintained | $21.00 | +149.7% | 08/13/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $21.00 | +149.7% | 08/10/2026 |
Michael Okunewitch Maxim Group | Buy | Reiterated | $20.00 | +137.8% | 08/07/2026 |
Madison Elsaadi B. Riley Securities | Buy | Maintained | $22.00 | +161.6% | 08/06/2026 |
Judah Frommer Morgan Stanley | Buy | Maintained | $18.00 | +114% | 08/06/2026 |
Leonid Timashev RBC Capital | Buy | Reiterated | $21.00 | +149.7% | 08/05/2026 |
Ritu Baral TD Cowen | Buy | Maintained | $29.00 | +244.8% | 08/05/2026 |
Thomas Shrader BTIG | Buy | Maintained | $25.00 | +197.3% | 07/07/2026 |
Rudy Li Wolfe Research | Buy | Maintained | $18.00 | +114% | 07/07/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $20.00 | +137.8% | 07/07/2026 |
Jason McCarthy Maxim Group | Buy | Reiterated | $20.00 | +137.8% | 05/15/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $18.00 | +114% | 05/14/2026 |
Next call in 4:06:07
Today, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.33
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 23.40M | 42.82M | 24.00M | 26.59M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 13.21M | 16.05M | 16.42M | 23.20M |
Operating expense | 36.61M | 58.86M | 40.43M | 49.79M |
Total operating expenses | 36.61M | 58.86M | 40.43M | 49.79M |
Operating income | -36.61M | -58.86M | -40.43M | -49.79M |
Other non operating income | -100.94M | -37.79M | 131.40M | -205.03M |
EBT including unusual items | -137.95M | -96.61M | 91.19M | -253.46M |
EBT excluding unusual items | -137.95M | -96.61M | 91.19M | -253.46M |
Income tax expense | -230.00K | -2.73M | -11.00K | 331.00K |
Effective tax rate | 0.17% | 2.83% | -0.01% | -0.13% |
Other operating expenses | - | - | - | - |
Net income | -137.72M | -93.88M | 91.20M | -253.79M |
Net profit margin | - | - | - | - |
Earnings per share | -0.38 | -0.61 | -0.30 | -0.36 |
Interest and investment income | 1.59M | 1.31M | 2.42M | 3.74M |
Interest expense | -1.10M | -1.14M | -1.46M | -1.48M |
Net interest expenses | 483.00K | 173.00K | 954.00K | 2.26M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -36.60M | -58.86M | -40.37M | -49.74M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events